165 related articles for article (PubMed ID: 36151018)
1. Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.
Wong V; de Boer R; Baron-Hay S; Blum R; Boyle F; Chua S; Clarke K; Cuff K; Green M; Lim E; Mok K; Nott L; Nottage M; Tafreshi A; Tsoi D; Uccellini A; Hong W; Gibbs P; Lok SW
Clin Breast Cancer; 2022 Dec; 22(8):792-800. PubMed ID: 36151018
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA; Decker T; Hartkopf A; Nusch A; Heinrich BJ; Kurbacher C; Fuchs R; Tesch H; Krabisch P; Huober J; Kuemmel S; Brucker S; Janni W; Schneeweiss A; Schuler M; Fehm T; Lüftner D; Quiering C; Voges C; Kreuzeder J; Reinisch M
Eur J Cancer; 2024 Feb; 198():113480. PubMed ID: 38154393
[TBL] [Abstract][Full Text] [Related]
3. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
[TBL] [Abstract][Full Text] [Related]
6. Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
Staropoli N; Geuna E; Rinaldi G; Bisagni G; Scotti V; Faggioni G; Vannini L; Arcara C; Moretti G; Gunnellini M; Coltelli L; Verderame F; Livi L; Sanna G; Grasso D; Abbinante G; Ragni F
Curr Oncol; 2022 Sep; 29(9):6635-6641. PubMed ID: 36135090
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
8. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Hortobagyi GN
Breast Cancer Res; 2018 Oct; 20(1):123. PubMed ID: 30340505
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Gao JJ; Osgood CL; Feng Z; Bloomquist EW; Tang S; Chang CJG; Ricks TK; Hou SC; Pierce WF; Rivera DR; Pazdur R; Kluetz PG; Amiri-Kordestani L
Clin Cancer Res; 2023 Dec; 29(24):5008-5011. PubMed ID: 37594723
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Borstnar S; Palacova M; Łacko A; Timcheva C; Gal-Yam EN; Papazisis K; Beniak J; Kudela P; Rubovszky G
Radiol Oncol; 2022 May; 56(2):238-247. PubMed ID: 35575587
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Yardley DA; Hart L; Favret A; Blau S; Diab S; Richards D; Sparano J; Beck JT; Richards P; Ward P; Ramaswamy B; Tsai M; Blackwell K; Pluard T; Tolaney SM; Esteva FJ; Truica CI; Alemany C; Volas-Redd G; Shtivelband M; Purkayastha D; Dalal AA; Miller M; Hortobagyi GN
Clin Breast Cancer; 2019 Aug; 19(4):268-277.e1. PubMed ID: 31160171
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
14. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
Lu YS; Im SA; Colleoni M; Franke F; Bardia A; Cardoso F; Harbeck N; Hurvitz S; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; O'Regan R; Gasch C; Solovieff N; Wang C; Wang Y; Chakravartty A; Ji Y; Tripathy D
Clin Cancer Res; 2022 Mar; 28(5):851-859. PubMed ID: 34965945
[TBL] [Abstract][Full Text] [Related]
15. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole
Jhaveri K; O'Shaughnessy J; Fasching PA; Tolaney SM; Yardley DA; Sharma VK; Biswas C; Thuerigen A; Pathak P; Rugo HS
Ther Adv Med Oncol; 2023; 15():17588359231216095. PubMed ID: 38107828
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
18. Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Kristensen KB; Thomsen IMN; Berg T; Kodahl AR; Jensen AB
Breast Cancer Res Treat; 2021 Aug; 188(3):799-809. PubMed ID: 33837869
[TBL] [Abstract][Full Text] [Related]
19. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Janni W; Alba E; Bachelot T; Diab S; Gil-Gil M; Beck TJ; Ryvo L; Lopez R; Tsai M; Esteva FJ; Auñón PZ; Kral Z; Ward P; Richards P; Pluard TJ; Sutradhar S; Miller M; Campone M
Breast Cancer Res Treat; 2018 Jun; 169(3):469-479. PubMed ID: 29404806
[TBL] [Abstract][Full Text] [Related]
20. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
